These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21549509)

  • 21. Comparison of HPA axis hormonal responses to naloxone vs psychologically-induced stress.
    Oswald LM; Mathena JR; Wand GS
    Psychoneuroendocrinology; 2004 Apr; 29(3):371-88. PubMed ID: 14644067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene.
    Geer EB; Landman RE; Wardlaw SL; Conwell IM; Freda PU
    Pituitary; 2005; 8(2):115-22. PubMed ID: 16379031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.
    Johansson J; Hirvonen J; Lovró Z; Ekblad L; Kaasinen V; Rajasilta O; Helin S; Tuisku J; Sirén S; Pennanen M; Agrawal A; Crystal R; Vainio PJ; Alho H; Scheinin M
    Neuropsychopharmacology; 2019 Aug; 44(9):1667-1673. PubMed ID: 30867551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diurnal effects of fluoxetine and naloxone on the human hypothalamic-pituitary-adrenal axis.
    Torpy DJ; Grice JE; Hockings GI; Walters MM; Crosbie GV; Jackson RV
    Clin Exp Pharmacol Physiol; 1997 Jun; 24(6):421-3. PubMed ID: 9171947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade.
    Wand GS; McCaul M; Yang X; Reynolds J; Gotjen D; Lee S; Ali A
    Neuropsychopharmacology; 2002 Jan; 26(1):106-14. PubMed ID: 11751037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys.
    Pascoe JE; Williams KL; Mukhopadhyay P; Rice KC; Woods JH; Ko MC
    Psychoneuroendocrinology; 2008 May; 33(4):478-86. PubMed ID: 18325678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diurnal variations in endocrine and psychological responses to 0.2 mg/kg naloxone administration in patients with major depressive disorder and matched controls.
    Martín del Campo AF; Dowson JH; Herbert J; Paykel ES
    J Affect Disord; 2000; 57(1-3):37-47. PubMed ID: 10708814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amygdalar vasopressin mRNA increases in acute cocaine withdrawal: evidence for opioid receptor modulation.
    Zhou Y; Bendor JT; Yuferov V; Schlussman SD; Ho A; Kreek MJ
    Neuroscience; 2005; 134(4):1391-7. PubMed ID: 16039786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose naloxone (1.0 mg/kg): psychological and endocrine effects in normal male subjects pretreated with one milligram of dexamethasone.
    Martín-Del-Campo AF; Cortés-Sotres J; Herrera-Ferrá K; Ulloa-Aguirre A
    Psychoneuroendocrinology; 1998 May; 23(4):413-24. PubMed ID: 9695140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid modulation of the fetal hypothalamic-pituitary-adrenal axis: the role of receptor subtypes and route of administration.
    Taylor CC; Wu D; Soong Y; Yee JS; Szeto HH
    J Pharmacol Exp Ther; 1997 Apr; 281(1):129-35. PubMed ID: 9103489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OPRM1 gene variation influences hypothalamic-pituitary-adrenal axis function in response to a variety of stressors in rhesus macaques.
    Schwandt ML; Lindell SG; Higley JD; Suomi SJ; Heilig M; Barr CS
    Psychoneuroendocrinology; 2011 Oct; 36(9):1303-11. PubMed ID: 21459516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of body mass on the hypothalamic-pituitary-adrenal-axis response to naloxone in patients with polycystic ovary syndrome.
    Guido M; Ciampelli M; Fulghesu AM; Pavone V; Barini A; de Marinis L; Cento R; Caruso A; Lanzone A
    Fertil Steril; 1999 Mar; 71(3):462-7. PubMed ID: 10065783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypothalamic-pituitary-adrenal axis and ethanol modulation of deoxycorticosterone levels in cynomolgus monkeys.
    Porcu P; Grant KA; Green HL; Rogers LS; Morrow AL
    Psychopharmacology (Berl); 2006 Jun; 186(3):293-301. PubMed ID: 16133132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of flumazenil on basal and naloxone-stimulated ACTH and cortisol release in humans.
    Torpy DJ; Jackson RV; Grice JE; Hockings GI; Crosbie GV; Walters MM
    Clin Exp Pharmacol Physiol; 1994 Feb; 21(2):157-61. PubMed ID: 8039271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions between the stimulated hypothalamic-pituitary-adrenal axis and leptin in humans.
    Nye EJ; Bornstein SR; Grice JE; Tauchnitz R; Hockings GI; Strakosch CR; Jackson RV; Torpy DJ
    J Neuroendocrinol; 2000 Feb; 12(2):141-5. PubMed ID: 10718909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine.
    Boushaki FZ; Rasio E; Serri O
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):461-6. PubMed ID: 9196609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls.
    Buckley TM; Mullen BC; Schatzberg AF
    Psychoneuroendocrinology; 2007; 32(8-10):859-64. PubMed ID: 17666187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adrenocortical responses and family history of alcoholism.
    Wand GS; Mangold D; Ali M; Giggey P
    Alcohol Clin Exp Res; 1999 Jul; 23(7):1185-90. PubMed ID: 10443984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1).
    Hernandez-Avila CA; Wand G; Luo X; Gelernter J; Kranzler HR
    Am J Med Genet B Neuropsychiatr Genet; 2003 Apr; 118B(1):60-5. PubMed ID: 12627468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.
    Weerts EM; Wand GS; Kuwabara H; Xu X; Frost JJ; Wong DF; McCaul ME
    Addict Biol; 2014 Jul; 19(4):733-42. PubMed ID: 23252742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.